{"disease":{"id":"gastric-neuroendocrine-carcinoma","name":"gastric neuroendocrine carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06663852","title":"ML Decision Model for G-NEC Adjuvant Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":1505,"lead_sponsor_name":"Chang-Ming Huang, Prof.","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05671393","title":"the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":801,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT04483349","title":"Assessment of What Patients and Healthcare Providers Value","phase":"","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03935893","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Udai Kammula","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT02595424","title":"Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":67,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT07118176","title":"Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06102746","title":"Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}